OR WAIT null SECS
June 29, 2024
This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.
June 28, 2024
Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.
June 13, 2024
Key information is needed for excipients and their potential impact on continuous manufacturing processes.
Syngene's new production platform offers rapid protein synthesis with lower risk.
May 30, 2024
Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.
FDA granted priority review to Sanofi's sBLA for Sarclisa in combination with VRd in treating transplant-ineligible patients who are newly diagnosed with multiple myeloma.
Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.
May 25, 2024
The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.
May 24, 2024
With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.
May 20, 2024
The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.
